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BACKGROUND: Apha-2 agonists are combined with local anesthetics to extend the duration of regional 
anesthesia. We evaluated the effect of combining dexmedetomidine with levobupivacine with respect to 
duration of motor and sensory block and duration of analgesia. 
METHODS: Sixty patients scheduled for elective forearm and hand surgery were divided into two equal 
groups in a randomized double blind fashion. The patients received brachial plexus block via 
supraclavicular route with the help of nerve stimulator. In group L (n=30) 35cc of levobupivacaine with 
1ml of isotonic saline and in group LD (n=30) 35cc of levobupivacine with 1 ml of (100 microgram) of 
dexmedetomidine was given. Duration of motor and sensory block and time to first rescue analgesia were 
recorded. Data analysis was done by SPSS version 16.0 [SPSS Inc ILLINOIS, USA, 2008]. Categorical 
variables were analyzed using Pearson”s Chi-square test. Normally distributed numerical variables were 
analyzed using unpaired “t” test. Skewed numerical variables within the group were analyzed using 
Man-Whitney “U” test.  All tests were two tailed. Statistical significance was defined as P<0.05. 
RESULTS:  Sensory and motor block durations were longer in group LD as compared to L (P<0.01). 
Duration of analgesia was significantly longer in group LD as compared to group L (p<0.05).  
CONCLUSION: Dexmedetomidine added to levobupivacaine in supraclavicular brachial plexus block 
prolongs the duration of block and the duration of postoperative analgesia. 
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INTRODUCTION  
Upper limb surgeries are preferably done under 
regional anesthesia. Peripheral nerve blocks not 
only provide for intra operative anesthesia but also 
ensure analgesia in the post operative period 
without any systemic side effects (1). 
Levobupivacaine, a new local anesthetic having, 
similar pharmacological profile, but was shown to 
posses less cardiotoxicity when compared to 
Bupivacaine (2). 
There has always been a search for ideal 
adjuvants in peripheral nerve blocks which 
prolong the duration of analgesia with lesser 
adverse effects. Although the search continues we 
decided to use the new α2 adrenergic agonist, 
dexmedetomidine which is 8(eight) times more 
selective towards α2 adrenoreceptors compared to 
clonidine (3).Clinical studies have shown opoid 
sparing effects of dexmedetomidine when used 
intravenously along with decrease in inhalational 
anesthetic requirement (4). It has also been 
reported to improve quality of intrathecal and 
epidural anesthesia (5, 6). However, very few 
clinical trials have studied the effect of 
dexmedetomidine in supraclavicular brachial 
plexus block. 
We decided to investigate the effects of 
adding dexmedetomidine to levobupivacine in 
supraclavicular brachial plexus block. Our primary  
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aim was to study the duration of motor and 
sensory blocks as well as time required to first 




Institutional ethics committee approval was 
obtained. Seventy (70) American Society of 
Anesthesiologist (ASA) physical status patients 
scheduled for elective orthopaedic surgery of 
forearm and hand were enrolled in a prospective 
double blind controlled trial after obtaining written 
informed consent from the patients. After those 
who failed to satisfy the selection criteria were 
excluded the remaining patients were allocated 
into two groups of thirty patients (n=30) each 
using computer generated random number table in 
a double blinded manner into two groups L and 
LD to receive 35 cc of levobupivacaine 
(Levoanawin, Neon Laboratories, Mumbai)0.5% 
with 1 ml of isotonic normal saline and 35 cc of 
levobupivacaine(Levoanawin, Neon Laboratories, 
Mumbai)0.5% with 1 ml (100microgram[µg]) of 
demedetomidine (Dextomid  Neon Laboratories, 
Mumbai) respectively. 
Blinding was ensured in the following 
manner: 
 The patients were unaware of the study drug 
administered. 
 A different anesthesiologist not involved in 
the post operative monitoring performed the 
brachial plexus block and was unaware of 
group allocation and drug being 
administered. 
 The statistician who analyzed the results was 
unaware of group allocation and aim of the 
study 
 The local anesthetic solution was prepared by 
the hospital central pharmacy in coded 
transparent syringes labeled with the patients 
study number. In the case of emergency 
related or possibly related to the study or 
study drugs, the pharmacist was authorized to 
disclose the contents of the syringe to staff 
anesthetist. The study blinding was broken 
after the statistical analysis. 
Patients on adrenoreceptor agonist or 
antagonist therapy; history of bleeding disorders; 
history of cardiac, respiratory, renal failure; and 
pregnant women were excluded from the study. 
On arrival of the patients in the operation room 
baseline heart rate, blood pressure, and oxygen 
saturation were recorded. An intravenous line with 
a 18-gauge (G) intravenous (iv) cannula was 
secured in the unaffected limb and Ringer’s 
Lactate infusion was stared. All patients received 
brachial plexus block through the supraclavicular 
route by an experienced anesthesiologist. Neural 
localization was achieved by a nerve locator 
(Fisher and Paykel, New Zeland) connected to a 
22 G, 50-mm-long stimulating needle (Stimuplex, 
Braun, Germany). The location end point was a 
distal motor response with an output lower than 
0.5 mA (miliampers) in the median nerve region. 
Following negative aspiration the local anesthetic 
solution in the labeled coded syringe was injected. 
Sensory block was assessed by pin prick 
method. Sensory onset was considered when there 
was dull sensation to pin prick along the 
distribution of any two of the three nerves (median 
nerve, radial nerve, ulnar nerve, musculocutenous 
nerve). Complete sensory block was considered 
when there was complete loss of sensation to pin 
prick. Sensory block was graded as: 
 Grade 0: Sharp pin felt 
 Grade 1: Analgesia, dull sensation felt 
 Grade 2: Anesthesia, no sensation felt 
Motor block assessment was done according to 
modified Bromage scale for upper extremities on a 
three point scale: 
 Grade 0:  normal motor function with full 
flexion and extension of elbow, wrist and 
fingers. 
 Grade 1:  decreased motor strength with 
ability to move fingers only. 
 Grade 2:  complete motor block with 
inability to move fingers. 
Sensory and motor blocks were evaluated 
every 3 minutes until 30 minutes after injection, 
and then every 30 minute until they have resolved. 
Complete sensory block was defined by anesthetic 
block (Grade 2) on all nerve territories. Duration 
of sensory block was defined as time interval 
between the end of administration of local 
anesthetic and complete resolution of anesthesia 
on all nerves. Complete motor block was defined 
as absence of voluntary movement on fingers 
(Grade 2). Duration of motor block was defined as 
the time interval between the end of local 




anesthetic administration and the recovery of 
complete motor function of the hand and forearm. 
Patients were monitored for Heart Rate(HR), 
systolic arterial blood pressure(SBP), diastolic 
arterial blood pressure(DBP), Arterial oxygen 
saturation(SpO2) at an interval of 5 minutes intra 
operatively and every 15 minutes post operatively. 
Pain was assessed using the Visual Analog 
Scale (VAS) (0-10). Nursing staff administered IV 
Supridol (tramadol, Neon Laboratories, Mumbai) 
100 mg when the VAS >4. The time between the 
end of local anesthetic administration and the first 
analgesic request was noted as the duration of 
analgesia. 
All raw data were analyzed by SPSS 
(statistical package for social sciences) version 
16.0 (SPSS inc ILLINOIS, USA, 2008). 
Categorical variables were analyzed using 
Pearson’s Chi square test. Normally distributed 
numerical variables were analyzed using unpaired 
“t” test. Skewed numerical variables within the 
group were analyzed using Man-Whitney “U” test.  





Seventy (70) patients posted for upper limb 
surgeries were assessed for suitability to enroll in 
the study. 7(seven) patients declined to participate 
in the study. 3 patients were excluded as they were 
found to be on anticoagulation drugs. The 
remaining 60 patients fulfilling the inclusion 
criteria were randomly assigned to the two study 
groups. 
 Both groups were comparable in terms of 
age, height and weight (2-tailed independent 
sample “t” test) and sex distribution (Chi-square 
test). The surgical characteristics were also similar 
in both the groups in the Chi-square test (Table 1). 
 




   ( n=30) X±SD   
 Group-LD 
 ( n=30) X±SD 
Age(Years) 32.56± 10.06  30.34±12.98            
 Height(Cm)  170.34±10.08            167.45±11.08                
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The baseline haemodynamic parameters were 
comparable in both groups. SBP levels in group 
LD at 15, 60, 90, 120 minutes were significantly 
lower than in group L (P<0.05)(Mann-Whiteny U 
test) as shown in Fig 1. DBP levels in group LD at 
60, 90, 120 minutes were significantly lower than 
those in group L (p<0.05) (Fig-2). HR levels in 
group LD, except basal measurements were 




Fig. 1: Systolic blood pressure (SBP) between the 
groups (GR-L = group receiving levobupivcaine, GR-
LD= group receiving levobupivacaine and 
dexmedetomidine).  Significant difference at 15, 30, 90 




Fig. 2:  Diastolic blood pressure at 60, 90 and 
120 minutes showed significant statistical 
difference between the two study groups. 
L=levobupivacaine; LD=levobupivacaine & 
dexmedetomidine  DBP=Diastolic blood pressure 
 







Fig. 3: Excluding basal heart rate the heart rate 
in group-LD was significantly lower than group-L 
L---Levobupivacine LD----Levobupivacine & 
Dexmeditomidine. 
 
Sensory and motor blockade duration were longer in 
group LD than group L (P<0.01) (Mann-Whiteny 
U test). Duration of analgesia was significantly 
longer in group LD (997±154.23minutes) than in 
group L (801.13±200.08minutes) (P<0.05) (Mann-
Whiteny U test) as can be seen in Table-2. No side 
effects-including nausea, vomiting, hypotension, 
and hypoxemia—were reported in either group. 
 
Table 2: Duration of sensory and motor block, duration 
of postoperative analgesia in the two study groups 
 
  Group L 
  (n=30)        
(X±SD) 
 Group-LD 
  (n=30)        
(X±SD) 
Duration of motor 
block (minutes) 
 512± 60.13  840±50.23                
Duration of sensory 
block (minutes) 
 645± 70.11  898±32.33                 
Duration of 
analgesia(minutes) 
          
801.13±200.08 





In this study we demonstrated that in patients 
undergoing supraclavicular brachial plexus block 
addition of dexmedetomidine to levobupivacaine 
prolongs the duration of sensory and motor 
blockade as well as time to rescue analgesia. The 
mechanism by which α2 adrenergic receptor 
agonists produce analgesia and sedation is not 
fully understood but is likely to be multifactorial. 
Peripherally, α2agonists produce analgesia by 
reducing release of norepinephrine and causing α2 
receptor-independent inhibitory effects on nerve 
fiber action potentials. Centrally, α2 agonists 
produce analgesia and sedation by inhibiting 
substance P release in the nociceptive pathway at 
the level of the dorsal root neuron and by 
activating α2 adrenoceptors in the locus coeruleus 
(7, 8). 
A study by Brumett et al (9) showed that 
dexmedetomidine enhances duration of 
bupivacaine anaesthesia and analgesia of sciatic 
nerve block in rats without any damage to nerve. 
Histopathological evaluation of the nerve axon 
and myelin were normal in both groups were 
normal at 24 hours and 14 days. In another study 
by same authors perineural demedetomidine added 
to ropivacaine for siatic nerve block in rats 
prolonged the duration of analgesia by blocking 
the hyperpolarization –activated cationic channel 
(10). This shows peripheral action of 
dexmedetomidine was caused by activation of 
hyperpolarization activated cation current which 
prevents the nerve from returning from 
hyperpolarized state to resting membrane potential 
for subsequent firing. Kousugi et al in their study 
found high concentrations of dexmedetomidine 
inhibit compound action potentials in frog siatic 
nerves without α2 adrenorecptors activation in a 
concentration dependent manner and reversibly 
(11). 
The efficacy of perineural dexmedetomidine 
for analgesia has been established. This effect is 
dose dependent and the effect is peripheral (not 
caused by centrally mediated or systemic 
analgesia). 
However all studies carried out so far to 
peripheral action of α2 agonists were animal 
studies. Very few human trials have been 
conducted. Several studies have found 
dexmedetomidine to be safe and effective in 
various neuraxial and regional anesthesia 
techniques including intrathecal and I.V. regional 
anesthesia (5,12,13).  A dexmedetomidine –
lidocaine mixture has been used to provide Bier”s 
block and was shown to improve the quality of 
anesthesia and tourniquet pain and reduce 
postoperative analgesic requirement (12,13). 
Keeping these facts in mind we decided to 
compare the effects of addition of 




dexmedetomidine with levobupivacaine in 
peripheral nerve block. 
Some studies have shown that addition of 
clonidine to local anesthetics in brachial plexus 
block have extended the duration of anesthesia 
and increased the quality of analgesia, (14) but 
Erlacher et al failed to find any advantage of 
addition of clonidine 100µ to 0.75% 40ml of 
ropivacaine . They concluded that ropivacaine 
itself having vasoconstrictor properties adding α2 
adrenergic agonist did not increase the effect (15).
 
Motor and sensory block was significantly 
prolonged on addition of dexmedetomidine which 
provided for better patient compliance in the 
postoperative period. Swami et al in their study 
showed significant increase in duration of 
analgesia on addition of dexmedetomidine to 
bupivacine 0.25% in brachial plexus block (16). 
We were concerned with minimal patient 
discomfort in the postoperative period due to 
prolongation of motor block. 
None of the patients in group LD required 
any sedation which can be explained on the basis 
of some amount of systemic absorption of the drug 
(17). Αs α2 agonists produce sedation by central 
action by inhibition of substance P release in the 
nociceptive pathway at the level of dorsal root 
neuron and by activation of α2 adrenoreceptors in 
locus coeruleus. 
We were unable to use ultrasound guided 
blocks due to its unavailability in our institution at 
the time of our study which could have helped us 
to lower doses and volume of local anesthetic. 
Although clonidine still continues to be used 
widely as compared with dexmedtomidine 
probably due to its lower cost but we would like to 
suggest this new α2 receptor agonist as a better 
alternative. We admit that further trials are 
necessary to determine the cost effectiveness of 
the drug. To conclude 100µg of dexmedetomidine 
when added to levobupivacine 0.5% in 
supraclavicular brachial plexus block prolongs the 
duration of motor and sensory block and extends 
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